Medipet Dog Fresh Breath Foaming Mousse 150ml

Product Information

Hoarseness and candidiasis of the mouth and throat (thrush) occurs in some patients. Such patients may find it helpful to rinse out their mouth with water after using the inhaler. Symptomatic candidiasis can be treated with topical anti-fungal therapy whilst still continuing with Flixotide Evohaler. Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decreased bone mineral density, cataract, glaucoma

Fluticasone propionate given by inhalation at recommended doses has a potent glucocorticoid anti-inflammatory action within the lungs, resulting in a reduction of both symptoms and exacerbations of asthma, with a lower incidence and severity of adverse effects than those observed when corticosteroids are administered systemically. The dose should be titrated down to the lowest dose at which effective control of asthma is maintained. If patients find that relief with short-acting bronchodilator treatment becomes less effective or they need more inhalations than usual, medical attention must be sought. Many other items have been import from many countries by using OEM under the brand of "Pet8" such as pet accessories, pet carrier, pet cage, pet toy, leash, collar, harness, pet sheet, Administration of doses above 1000 micrograms (500 micrograms twice daily) should be via a spacer device to help reduce side-effects in the mouth and throat. (See section 4.4)There have been very rare reports of increases in blood glucose levels, in patients with or without a history of diabetes mellitus (see section 4.8). This should be considered in particular when prescribing to patients with a history of diabetes mellitus. pet stroller and etc. We have our research team to expand and upgrade our product by searching new product and our customer needed. We are not just distribute our house brand, we also looking for other partner to distributed their product. We have been distributed many other item under their brand, and become a vital partner. We distributed under the brand "Cuddles",

Co-treatment with other potent CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side-effects.Subcutaneous embryofetal development studies in mouse and rat at 45 and 100 mcg/kg, respectively (approximately equivalent to 4 and 6 times the maximum recommended daily inhaled dose of 500 mcg twice daily in adults based on mouse and rat plasma levels of 486 and 710 pg/mL, respectively) resulted in fetal developmental toxicity characteristic of a potent corticosteroid, including cleft palate and embryonic fetal growth retardation, at doses that caused maternal toxicity. The no effect level for these finding in rat were associated with systemic exposures approximately 3 times the highest clinical exposure based on rat plasma level of 310 pg/mL. In the rabbit, fetal weight reduction and cleft palate occurred at a maternally toxic subcutaneous dose of 4 mcg/kg (less than 1.4 times the maximum recommended inhaled dose of 500 mcg twice daily based on rabbit plasma level of 149 pg/mL). However, fluticasone propionate administered via inhalation to rats did not induce teratogenicity at maternal toxic doses associated with exposures 17 times the human exposure achieved with the maximum recommended daily inhaled dose based on rat plasma level of 1890 pg/mL. There are limited data in pregnant women. Administration of fluticasone propionate during pregnancy should only be considered if the expected benefit to the mother is greater than any possible risk to the fetus. It is important, that the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control is maintained. Treatment with fluticasone propionate should not be stopped abruptly. Certain individuals can show greater susceptibility to the effects of inhaled corticosteroid than do most patients. Should Flixotide 50 microgram Evohaler presentation not offer the exact paediatric dose prescribed by the physician, please see data sheets of alternative Flixotide presentation (Accuhaler, Nebules). As with other inhalation therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing. Flixotide Evohaler should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary.